Ocugen, Bharat Biotech sign agreement for commercialisation rights to COVAXIN in Canada
Similar to the US profit share arrangement, Ocugen will retain 45 per cent of the profits from sales of COVAXIN in Canada
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ocugen
Ocugen intends to sell 100 million doses of COVAXIN in US in 2021
Cracking the US market would be a significant milestone for the company and India’s vaccine industry
Ocugen, Bharat Biotech announce agreement for commercialisation of Covaxin in US market
Ocugen and Bharat Biotech have entered into a definitive agreement to co-develop, supply, and commercialise Bharat Biotech’s…
Ocugen and Bharat Biotech to Co-develop COVAXIN for US market
Ocugen will have US rights to the vaccine candidate and, in collaboration with Bharat Biotech, will be responsible for clinical…